Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer. The company leverages its proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its lead clinical candidates include JANX007, a PSMA-targeted TRACTr for metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeted TRACTr for various solid tumors such as colorectal cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, JANX011 is a CD19-targeted ARM being developed for autoimmune diseases. Janux also has strategic collaborations with Merck Sharp & Dohme and Bristol Myers Squibb to advance its pipeline.

Janux Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol JANX. The company's shares are traded in United States Dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, Janux is subject to the exchange's listing standards and regulatory requirements, providing investors with a regulated trading environment.

Janux Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies, particularly immunotherapies for cancer. The company's work involves advanced biological platforms to create treatments that activate the immune system against tumors, placing it at the forefront of biopharmaceutical innovation in oncology and autoimmune diseases.

Janux Therapeutics is headquartered in San Diego, California, United States. The company primarily serves the global cancer treatment market, with its clinical programs targeting various solid tumors and prostate cancer. Its research and development activities are centered in the U.S., but its collaborations with major pharmaceutical companies like Merck Sharp & Dohme and Bristol Myers Squibb indicate a broader international reach. Janux's therapies are designed for patients worldwide, though its clinical trials are currently conducted in the United States.

Janux Therapeutics is a clinical-stage biopharmaceutical company that does not yet have approved products or generate revenue from product sales. Its business model focuses on research and development of immunotherapies using its proprietary TRACTr, TRACIr, and ARM platforms. The company generates revenue through strategic collaborations and licensing agreements, such as its partnerships with Merck Sharp & Dohme and Bristol Myers Squibb. These collaborations typically involve upfront payments, milestone payments, and royalties on future product sales. Janux's long-term value depends on successfully advancing its pipeline through clinical trials and obtaining regulatory approval for its drug candidates.